NCT06200259 Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
| NCT ID | NCT06200259 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Covenant Health Cancer Center |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-12-15 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2025-12-15 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This purpose of this study is to examine the placement of proton spots during pencil beam scanning proton therapy for low and intermediate risk prostate cancer. The researchers will test a unique technique called "Spot Delete" to control the placement of spots during treatment planning. They will also use a special computer model to study how the energy of the proton beam (linear energy transfer) is related to rectal and bladder side effects. The study involves creating a treatment plan based on a CT scan, which helps guide the proton beam in the body. The clinical team uses this CT scan to find the best placement for the protons. The "Spot Delete" method prevents protons from stopping in the rectum, sigmoid, and small bowel, which is thought to be related to acute or late toxicities, such as tenesmus, diarrhea, fecal incontinence, proctitis, and rectal hemorrhage.
Eligibility Criteria
Inclusion Criteria: * Pathological proven diagnosis of prostatic adenocarcinoma * History and physical exam to establish clinical staging * Clinical stage T1-T2c (AJCC 7th edition) * Prostate specific antigen (PSA) \< 20 ng/mL * Gleason Score ≤ 7 * Eastern Cooperative Oncology Group (ECOG) Performance status 0-1 * Patients must be 18 years of age or older * Willingness and ability to complete the International Prostate Symptom Score (IPSS) survey and Expanded Prostate Cancer Index Composite (EPIC) questionnaire Exclusion Criteria: * Prior radiotherapy to the pelvic area * Prior prostate cancer therapy: cryotherapy or hyperthermia * Prior systemic therapy (chemotherapy) for prostate cancer * Regional lymph nodes (common iliac, external iliac, internal iliac, presacral) are a target of treatment * Active diverticulitis, ulcerative colitis, or Crohn's disease
Contact & Investigator
Samantha Hedrick, PhD, DABR
PRINCIPAL INVESTIGATOR
Thompson Proton Center
Frequently Asked Questions
Who can join the NCT06200259 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06200259 currently recruiting?
Yes, NCT06200259 is actively recruiting participants. Contact the research team at shedrick@covhlth.com for enrollment information.
Where is the NCT06200259 trial being conducted?
This trial is being conducted at Knoxville, United States.
Who is sponsoring the NCT06200259 clinical trial?
NCT06200259 is sponsored by Covenant Health Cancer Center. The principal investigator is Samantha Hedrick, PhD, DABR at Thompson Proton Center. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.